KR100855569B1 - 항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 - Google Patents
항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 Download PDFInfo
- Publication number
- KR100855569B1 KR100855569B1 KR1020060126064A KR20060126064A KR100855569B1 KR 100855569 B1 KR100855569 B1 KR 100855569B1 KR 1020060126064 A KR1020060126064 A KR 1020060126064A KR 20060126064 A KR20060126064 A KR 20060126064A KR 100855569 B1 KR100855569 B1 KR 100855569B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- dihydro
- dioxo
- carboxylate
- alkyl
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
적용화합물 | 최소발육 저지농도(MIC)(㎍/㎖) | ||||
C. 알비칸스 | C. 그라브라타 | C. 트로피칼리스 | C. 파라시로시스 | C. 네오포르만스 | |
화합물 1 | 1.6 | 3.2 | 3.2 | 6.3 | 12.5 |
화합물 2 | 1.6 | 3.2 | 3.2 | 25.0 | 6.3 |
화합물 3 | 6.3 | 6.3 | 12.5 | 25.0 | 6.3 |
화합물 4 | 6.3 | 12.5 | 12.5 | 25.0 | 12.5 |
화합물 5 | 12.5 | 12.5 | 25.0 | 6.3 | 12.5 |
화합물 6 | 12.5 | 6.3 | <0.8 | 25.0 | 12.5 |
화합물 7 | 6.3 | 3.2 | 3.2 | 25.0 | 3.2 |
화합물 8 | 12.5 | 12.5 | 12.5 | 100.0 | 12.5 |
화합물 9 | 12.5 | 12.5 | 100 | 3.2 | 6.3 |
화합물 10 | 12.5 | 6.3 | <0.8 | 25.0 | 12.5 |
화합물 11 | 6.3 | 25 | 3.2 | 3.2 | <0.8 |
화합물 12 | 6.3 | 12.5 | 12.5 | 25.0 | 12.5 |
화합물 13 | 12.5 | 50 | 100 | 3.2 | 6.3 |
화합물 14 | 12.5 | 50 | 50 | 12.5 | 3.2 |
화합물 15 | 25 | 12.5 | 100 | 25 | 12.5 |
화합물 16 | 3.2 | 12.5 | 50 | 6.3 | 25 |
화합물 17 | 25 | 50 | 50 | 25 | 12.5 |
화합물 18 | 100 | 3.2 | 6.3 | 6.3 | 12.5 |
플루코나졸 | 25.0 | 25.0 | 100.0 | 12.5 | 25.0 |
케토코나졸 | 12.5 | 12.5 | 12.5 | 12.5 | 12.5 |
적용 화합물 | ED50± SD (n=5), (㎎/㎏) |
화합물 1 | 0.06± 0.03 |
화합물 2 | 0.07± 0.03 |
화합물 3 | 0.06± 0.03 |
화합물 4 | 0.40± 0.25 |
케토코나졸 | 6.00± 1.70 |
Claims (9)
- 제 1 항에 있어서,X가 메틸, 페닐, 또는 할로겐, C1 -5 알킬 또는 C1 -2 알콕시로 치환된 페닐이고; R2 및 R3가 메틸이거나 서로 결합하여 1개의 질소 원자를 함유하는 방향족 6원 헤테로고리를 형성하는 것을 특징으로 하는, 인돌다이온 유도체 또는 이의 약학적으로 허용되는 염.
- 제 2 항에 있어서,에틸 2-아미노-4,7-다이하이드로-1,5,6-트라이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-1,5,6-트라이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1-페닐-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1-p-톨릴-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-1-(4-메톡시페닐)-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-5,6-다이메틸-1-(3,4-다이메틸페닐)-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1-(4-트라이플루오로메톡시)페닐)-1H-인돌-3-카복실레이트,메틸 1-(4-클로로페닐)-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 1-(4-브로모페닐)-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1H-인 돌-3-카복실레이트,메틸 4,7-다이하이드로-(1-4-아이오도페닐)-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 1-(4-에틸페닐)-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 4,7-다이하이드로-1-(4-아이소프로필페닐)-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-1-(4-플루오로페닐)-4,7-다이하이드로-5,6-다이메틸-4,7-다이옥소-1H-인돌-3-카복실레이트,메틸 2-아미노-4,9-다이하이드로-4,9-다이옥소-1-p-톨릴-1H-피롤로[3,2-g]퀴놀린-3-카복실레이트,메틸 2-아미노-1-(4-플루오로페닐)-4,9-다이하이드로-4,9-다이옥소-1H-피롤로[3,2-g]퀴놀린-3-카복실레이트,메틸 2-아미노-4,9-다이하이드로-4,9-다이옥소-1-p-톨릴-1H-피롤로[3,2-g]퀴놀린-3-카복실레이트,메틸 2-아미노-4,9-다이하이드로-1-(4-메톡시페닐)-4,9-다이옥소-1H-피롤로[3,2-g]아이소퀴놀린-3-카복실레이트, 또는메틸 2-아미노-4,9-다이하이드로-4,9-다이옥소-1-페닐-1H-피롤로[3,2-g]아이소퀴놀린-3-카복실레이트인 것을 특징으로 하는, 인돌다이온 유도체 또는 이의 약학적으로 허용되는 염.
- (a) 알콜 용매 중에서 하기 화학식 19의 화합물을 C1 -5 알킬 시아노아세테이트와 반응시켜 하기 화학식 20의 화합물을 제조한 후, (b) 이를 알콜 용매 중에서 C1-5 알킬아민, 또는 할로겐, C1-5 알킬 또는 C1-5 알콕시로 치환되거나 치환되지 않은 페닐아민과 반응시키는 것을 포함하는, 하기 화학식 1a의 화합물의 제조방법:[화학식 1a][화학식 19][화학식 20]상기 식에서,R1은 C1 -5 알킬이고;X는 C1 -5 알킬, 또는 할로겐, C1 -5 알킬 또는 C1 -5 알콕시로 치환되거나 치환되지 않은 페닐이고;R'2 및 R'3은 각각 독립적으로 C1 -5 알킬이다.
- 제 4 항에 있어서,단계 (a)의 반응을 실온 내지 100℃의 온도 범위에서 2 ∼ 6 시간 동안 수행하고, 단계 (b)의 반응을 실온에서 2 ∼ 5 시간 동안 수행하는 것을 특징으로 하는 방법.
- (a) 알콜 용매 중에서 하기 화학식 21의 화합물을 C1 -5 알킬 시아노아세테이트와 반응시켜 하기 화학식 22의 화합물을 제조한 후, (b) 이를 알콜 용매 중에서 C1-5 알킬아민, 또는 할로겐, C1-5 알킬 또는 C1-5 알콕시로 치환되거나 치환되지 않은 페닐아민과 반응시키는 것을 포함하는, 하기 화학식 1b의 화합물의 제조방법:[화학식 1b][화학식 21][화학식 22]상기 식에서,R1은 C1 -5 알킬이고;X는 C1 -5 알킬, 또는 할로겐, C1 -5 알킬 또는 C1 -5 알콕시로 치환되거나 치환되지 않은 페닐이고;R"2 및 R"3은 서로 결합하여 1개의 질소 원자를 함유하는 방향족 6원 헤테로고리를 형성한다.
- 제 6 항에 있어서,단계 (a)의 반응을 실온 내지 100℃의 온도 범위에서 2 ∼ 6 시간 동안 수행하고, 단계 (b)의 반응을 실온에서 2 ∼ 5 시간 동안 수행하는 것을 특징으로 하는 방법.
- 제 1 항의 화학식 1의 인돌다이온 유도체 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 항진균용 조성물.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060126064A KR100855569B1 (ko) | 2006-12-12 | 2006-12-12 | 항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060126064A KR100855569B1 (ko) | 2006-12-12 | 2006-12-12 | 항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080054024A KR20080054024A (ko) | 2008-06-17 |
KR100855569B1 true KR100855569B1 (ko) | 2008-09-03 |
Family
ID=39801105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060126064A KR100855569B1 (ko) | 2006-12-12 | 2006-12-12 | 항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100855569B1 (ko) |
-
2006
- 2006-12-12 KR KR1020060126064A patent/KR100855569B1/ko not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
Indian Journal of Heterocyclic Chemistry (1999), 9(2), 113-118 |
Also Published As
Publication number | Publication date |
---|---|
KR20080054024A (ko) | 2008-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole | |
US20080249155A1 (en) | 5-Hydroxyindole-3-Carboxylate Derivatives and Uses Thereof | |
KR0173172B1 (ko) | Crf 길항제로서의 피롤로피리미딘 | |
JP3481900B2 (ja) | 含窒素複素環化合物 | |
US6316438B1 (en) | Fused pyridopyridazine inhibitors of cGMP phosphodiesterase | |
Zhang et al. | Design, synthesis, and biological evaluation of novel benzimidazole derivatives and their interaction with calf thymus DNA and synergistic effects with clinical drugs | |
US9540356B2 (en) | Compounds having a protective activity against toxins with intracellular activity | |
Jarrahpour et al. | Synthesis and biological evaluation of some new β-lactam-triazole hybrids | |
FI90235C (fi) | Menetelmä eläinlääketieteellisesti käyttökelpoisten -aryyli-4-(4,5-dihydro-3,5-diokso-1,2,4-triatsin-2(3H)-yyli)bentseeniasetonitriilien valmistamiseksi | |
DE60117835T2 (de) | Amino- substituierte tetracyclische Verbindungen,die als entzündungshemmende Mittel nützlich sind, und diese enthaltende Arzneimittel | |
CN107625766B (zh) | 一种噻唑类化合物用作抗菌增效剂的用途 | |
US20180186756A1 (en) | Disubstituted triazole analogs | |
Shekarchi et al. | Synthesis, Antibacterial and Antifungal Activities of 3-Aryl-5-(pyridin-3-yl)-4, 5-dihydropyrazole-1-carbothioamide Derivatives | |
KR20170023184A (ko) | 치환된 2-티옥소-이미다졸리딘-4-온 및 이의 스피로 유사체, 전립선암 치료용 항암 활성 성분, 약학적 조성물, 약제 제조 방법 및 치료 방법 | |
US20230303561A1 (en) | Pyrimidinone derivative, preparation method thereof and use thereof in resisting mycobacterium tuberculosis infection | |
Omprakash et al. | Synthesis, characterization and anti-microbial screening of novel heterocyclic system containing bridgehead nitrogen atom | |
EA012461B1 (ru) | Соединения, обладающие антимикобактериальной активностью | |
KR100855569B1 (ko) | 항진균 활성이 우수한 인돌다이온 유도체 및 이의 제조방법 | |
WO2016077541A1 (en) | Novel anti-infective compounds and methods using same | |
KR20080014017A (ko) | (5z)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5h)-온 | |
RU2487132C1 (ru) | Производные циклических 5-нитропиридин-2-ил-тиоалкенил-4-дитиокарбаматов, обладающие противогрибковой активностью, и их применение | |
Srikala et al. | Synthesis and Characterization of novel Spiroazetidin-2-ones tethered with Furans as Antimicrobial and Antiinflammatory agents | |
CZ280883B6 (cs) | 3-/1H-Indazol-3-yl/-4-pyridinaminy, způsob a meziprodukty pro jejich přípravu a jejich použití jako léčiv | |
US9290484B2 (en) | Furyl and thienyl triazole derivatives and therapeutic uses thereof | |
US20100324067A1 (en) | Tetracyclic dipyrano-coumarin compounds with anti-hiv and anti-mycobacterium tuberculosis activities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120718 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130826 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140801 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150825 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170222 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170821 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |